Matt Kelley, PhD

2013-2018 Neuroscience Tufts University, Boston 
 2018-2020 Neuroscience Amgen Inc., Thousand Oaks, CA, United States 
 2020-2021 Voyager Therapeutics 
 2021-2022 Pfizer 
"Matt Kelley"
Mean distance: 15.43 (cluster 11)
Cross-listing: Neuropathology Tree


Sign in to add mentor
Istvan Mody research assistant 2011-2013 UCLA
Stephen J. Moss grad student 2014-2018 Tufts
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Kelley MR, Cardarelli RA, Smalley JL, et al. (2018) Locally Reducing KCC2 Activity in the Hippocampus is Sufficient to Induce Temporal Lobe Epilepsy. Ebiomedicine
Moore YE, Kelley MR, Brandon NJ, et al. (2017) Seizing Control of KCC2: A New Therapeutic Target for Epilepsy. Trends in Neurosciences
Cairns DM, Chwalek K, Moore YE, et al. (2016) Expandable and Rapidly Differentiating Human Induced Neural Stem Cell Lines for Multiple Tissue Engineering Applications. Stem Cell Reports
Kelley MR, Deeb TZ, Brandon NJ, et al. (2016) Compromising KCC2 transporter activity enhances the development of continuous seizure activity. Neuropharmacology
Sivakumaran S, Cardarelli RA, Maguire J, et al. (2015) Selective Inhibition of KCC2 Leads to Hyperexcitability and Epileptiform Discharges in Hippocampal Slices and In Vivo. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 35: 8291-6
Silayeva L, Deeb TZ, Hines RM, et al. (2015) KCC2 activity is critical in limiting the onset and severity of status epilepticus. Proceedings of the National Academy of Sciences of the United States of America. 112: 3523-8
See more...